Localized In Vivo Electro Gene Therapy (<i>LiveGT</i>)-Mediated Skeletal Muscle Protein Factory Reprogramming
Gene electrotransfer (GET) has gained significant momentum as a non-viral gene delivery method for various clinical applications, primarily in the cancer immunotherapy and vaccine development space. Preclinical studies have demonstrated exogenous gene delivery and expression in various tissues, incl...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-12-01
|
| Series: | Applied Sciences |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-3417/14/23/11298 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850061370766131200 |
|---|---|
| author | Jacob Hensley Michael Francis Alex Otten Nadezhda Korostyleva Tina Gagliardo Anna Bulysheva |
| author_facet | Jacob Hensley Michael Francis Alex Otten Nadezhda Korostyleva Tina Gagliardo Anna Bulysheva |
| author_sort | Jacob Hensley |
| collection | DOAJ |
| description | Gene electrotransfer (GET) has gained significant momentum as a non-viral gene delivery method for various clinical applications, primarily in the cancer immunotherapy and vaccine development space. Preclinical studies have demonstrated exogenous gene delivery and expression in various tissues, including the liver, skin, cardiac muscle, and skeletal muscle. However, protein replacement applications of this technology have yet to be fully actuated. Plasmid DNA skeletal muscle delivery has been shown to maintain expression for up to 18 months. In the current study, we evaluated localized skeletal muscle delivery for protein replacement applications. We developed localized in vivo electro gene therapy (<i>liveGT</i>) protocols utilizing mono- and biphasic pulse sequences for localized pulse delivery directly to skeletal muscle with a custom monopolar platinum electrode. Plasmid DNA encoding human insulin and human glucokinase were chosen for this study to evaluate the <i>liveGT</i> platform for protein replacement potential. Initial in vitro GET was performed in mouse myoblasts to evaluate human insulin and glucokinase co-delivery. This was followed by <i>liveGT</i>-mediated reporter gene delivery in the skeletal muscle of Sprague–Dawley rats for pulse sequence selection. Protein replacement potential was evaluated in healthy (non-diabetic) rats with <i>liveGT</i>-mediated human insulin and glucokinase co-delivery to skeletal muscle. Human and rat insulin levels were measured via ELISA over the course of 3 months. Fed-state blood glucose measurements were monitored in correlation with serum human insulin levels. <i>LiveGT</i>-mediated skeletal muscle reprogramming successfully produced physiological levels of human insulin in serum over the course of 3 months. Hypo- and hyperglycemic events were not observed. Therefore, <i>liveGT</i> is a safe and viable platform for potential protein replacement therapies. |
| format | Article |
| id | doaj-art-b2a951ab28424a07b0d54421bcd7bae6 |
| institution | DOAJ |
| issn | 2076-3417 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Applied Sciences |
| spelling | doaj-art-b2a951ab28424a07b0d54421bcd7bae62025-08-20T02:50:16ZengMDPI AGApplied Sciences2076-34172024-12-0114231129810.3390/app142311298Localized In Vivo Electro Gene Therapy (<i>LiveGT</i>)-Mediated Skeletal Muscle Protein Factory ReprogrammingJacob Hensley0Michael Francis1Alex Otten2Nadezhda Korostyleva3Tina Gagliardo4Anna Bulysheva5Department of Medical Engineering, University of South Florida, Tampa, FL 33620, USAAsante Bio, Tampa, FL 33612, USADepartment of Medical Engineering, University of South Florida, Tampa, FL 33620, USADepartment of Medical Engineering, University of South Florida, Tampa, FL 33620, USADepartment of Medical Engineering, University of South Florida, Tampa, FL 33620, USADepartment of Medical Engineering, University of South Florida, Tampa, FL 33620, USAGene electrotransfer (GET) has gained significant momentum as a non-viral gene delivery method for various clinical applications, primarily in the cancer immunotherapy and vaccine development space. Preclinical studies have demonstrated exogenous gene delivery and expression in various tissues, including the liver, skin, cardiac muscle, and skeletal muscle. However, protein replacement applications of this technology have yet to be fully actuated. Plasmid DNA skeletal muscle delivery has been shown to maintain expression for up to 18 months. In the current study, we evaluated localized skeletal muscle delivery for protein replacement applications. We developed localized in vivo electro gene therapy (<i>liveGT</i>) protocols utilizing mono- and biphasic pulse sequences for localized pulse delivery directly to skeletal muscle with a custom monopolar platinum electrode. Plasmid DNA encoding human insulin and human glucokinase were chosen for this study to evaluate the <i>liveGT</i> platform for protein replacement potential. Initial in vitro GET was performed in mouse myoblasts to evaluate human insulin and glucokinase co-delivery. This was followed by <i>liveGT</i>-mediated reporter gene delivery in the skeletal muscle of Sprague–Dawley rats for pulse sequence selection. Protein replacement potential was evaluated in healthy (non-diabetic) rats with <i>liveGT</i>-mediated human insulin and glucokinase co-delivery to skeletal muscle. Human and rat insulin levels were measured via ELISA over the course of 3 months. Fed-state blood glucose measurements were monitored in correlation with serum human insulin levels. <i>LiveGT</i>-mediated skeletal muscle reprogramming successfully produced physiological levels of human insulin in serum over the course of 3 months. Hypo- and hyperglycemic events were not observed. Therefore, <i>liveGT</i> is a safe and viable platform for potential protein replacement therapies.https://www.mdpi.com/2076-3417/14/23/11298insulingene electrotransfer<i>liveGT</i>gene therapyglucoseprotein replacement therapy |
| spellingShingle | Jacob Hensley Michael Francis Alex Otten Nadezhda Korostyleva Tina Gagliardo Anna Bulysheva Localized In Vivo Electro Gene Therapy (<i>LiveGT</i>)-Mediated Skeletal Muscle Protein Factory Reprogramming Applied Sciences insulin gene electrotransfer <i>liveGT</i> gene therapy glucose protein replacement therapy |
| title | Localized In Vivo Electro Gene Therapy (<i>LiveGT</i>)-Mediated Skeletal Muscle Protein Factory Reprogramming |
| title_full | Localized In Vivo Electro Gene Therapy (<i>LiveGT</i>)-Mediated Skeletal Muscle Protein Factory Reprogramming |
| title_fullStr | Localized In Vivo Electro Gene Therapy (<i>LiveGT</i>)-Mediated Skeletal Muscle Protein Factory Reprogramming |
| title_full_unstemmed | Localized In Vivo Electro Gene Therapy (<i>LiveGT</i>)-Mediated Skeletal Muscle Protein Factory Reprogramming |
| title_short | Localized In Vivo Electro Gene Therapy (<i>LiveGT</i>)-Mediated Skeletal Muscle Protein Factory Reprogramming |
| title_sort | localized in vivo electro gene therapy i livegt i mediated skeletal muscle protein factory reprogramming |
| topic | insulin gene electrotransfer <i>liveGT</i> gene therapy glucose protein replacement therapy |
| url | https://www.mdpi.com/2076-3417/14/23/11298 |
| work_keys_str_mv | AT jacobhensley localizedinvivoelectrogenetherapyilivegtimediatedskeletalmuscleproteinfactoryreprogramming AT michaelfrancis localizedinvivoelectrogenetherapyilivegtimediatedskeletalmuscleproteinfactoryreprogramming AT alexotten localizedinvivoelectrogenetherapyilivegtimediatedskeletalmuscleproteinfactoryreprogramming AT nadezhdakorostyleva localizedinvivoelectrogenetherapyilivegtimediatedskeletalmuscleproteinfactoryreprogramming AT tinagagliardo localizedinvivoelectrogenetherapyilivegtimediatedskeletalmuscleproteinfactoryreprogramming AT annabulysheva localizedinvivoelectrogenetherapyilivegtimediatedskeletalmuscleproteinfactoryreprogramming |